Deutsch English Français

Contact

EP1160254

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1160254

EP1160254 - Human vanilloid receptor-like proteins [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 04.05.2007 Database last updated on 19.10.2024
Most recent event Tooltip	04.05.2007	Application deemed to be withdrawn	published on 06.06.2007 [2007/23]
Applicant(s)	For all designated states Pfizer Inc. 235 East 42nd Street New York, NY 10017 / US
	[N/P]
Former [2001/49]	For all designated states PFIZER INC. 235 East 42nd Street New York, N.Y. 10017 / US
Inventor(s)	01 / Shinjo, Katsuhiro, Pfizer Global Res. and Develop. 2, Aza 5-gochi, Taketoyo-cho Chita-gun, Aichi-ken 470-2393 / JP
	02 / Yabuuchi, Hikaru 4-14-3-202 Higashi-Rinkan Sagamihara-shi, Kanagawa 228-0811 / JP
	[2001/49]
Representative(s)	Hayles, James Richard, et al Pfizer ATTENTION: ADDRESS INACTIVE - USE ASS-NR - CDR / FR
	[N/P]
Former [2001/49]	Hayles, James Richard, et al Pfizer Limited, Patents Department, Ramsgate Road Sandwich Kent CT13 9NJ / GB
Application number, filing date	01304663.6	25.05.2001
	[2001/49]
Priority number, date	US20000208156P	31.05.2000 Original published format: US 208156 P
	[2001/49]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	EP1160254
	Date:	05.12.2001
	Language:	EN
	[2001/49]
Search report(s)	(Supplementary) European search report - dispatched on:	EP	12.10.2001
Classification	IPC:	C07K14/435, C07K14/705, C07K16/28, C12N15/11, C12Q1/68, C12N15/66, A61K38/17, A61P23/00	[2001/49]
	CPC:	C07K14/705 (EP,US); A61P11/06 (EP); A61P13/02 (EP); A61P15/00 (EP); A61P19/02 (EP); A61P21/00 (EP); (+) A61P23/00 (EP); A61P25/00 (EP); A61P25/02 (EP); A61P25/04 (EP); A61P29/00 (EP); A61P3/10 (EP); A61P35/00 (EP); A61P37/08 (EP); A61P41/00 (EP); A61P43/00 (EP); A61P9/00 (EP); A61P9/02 (EP); A61P9/12 (EP); A01K2217/05 (EP,US); A61K38/00 (EP,US) (-)
Designated contracting states	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR [2001/49]
Title	German:	Menschliche Vanilloid Rezeptor-änhliche Proteinen	[2001/49]
	English:	Human vanilloid receptor-like proteins	[2001/49]
	French:	Proteines humaines similaires au recepteur de la vanilloide	[2001/49]
Examination procedure	08.06.2001	Examination requested [2001/49]
	01.12.2006	Application deemed to be withdrawn, date of legal effect [2007/23]
	24.01.2007	Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2007/23]
Fees paid	Renewal fee
	11.04.2003	Renewal fee patent year 03
	20.04.2004	Renewal fee patent year 04
	31.05.2005	Renewal fee patent year 05
	Penalty fee
	Additional fee for renewal fee
	31.05.2006	06 M06 Not yet paid
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[A]WO9900115 (SMITHKLINE BEECHAM PLC [GB], et al) [A] 1,15-20 * the whole document *;
		[A]WO9937675 (UNIV CALIFORNIA [US], et al) [A] 1-21 * abstract * * page 2, line 35 - page 3, line 29 * * page 9, line 7 - page 10, line 2 * * page 11, lines 9-13 * * page 23, line 26 - page 26, line 20 * * page 29, line 19 - page 37, line 12 *;
		[PX]WO0032766 (GLAXO GROUP LTD [GB], et al) [PX] 1-20 * abstract * * SEQ.ID.N.5; page 2, line 34 - page 7, line 22; figure 19; examples 9-15 *;
		[PX]WO0050387 (PACIFIC CORP [KR], et al) [PX] 1,15-20 * the whole document *;
		[PX]WO0134805 (ABBOTT LAB [US]) [PX] 1-20 * SEQ.ID.N.1; page 2, line 10 - page 3, line 30; figure 8; examples 1,2,6,10,12-14 *;
		[AD] - CATERINA M J ET AL, "THE CAPSAICIN RECEPTOR: A HEAT-ACTIVATED ION CHANNEL IN THE PAIN PATHWAY", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, (19971023), vol. 389, ISSN 0028-0836, pages 816 - 824, XP002075020 [AD] 1-12 * the whole document * DOI: http://dx.doi.org/10.1038/39807
		[A] - ACS G ET AL, "TRIFLUOROPERAZINE MODULATES (3H)RESINIFERATOXIN BINDING BY HUMAN AND RAT VANILLOID (CAPSAICIN) RECEPTORS AND AFFECTS 45CA UPTAKE BY ADULT RAT DORSAL ROOT GANGLION NEURONES", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND, US, (19950901), vol. 274, no. 3, ISSN 0022-3565, pages 1090 - 1098, XP000864508 [A] 15-17,19 * the whole document *
		[A] - WALPOLE C S J ET AL, "THE DISCOVERY OF CAPSAZEPINE, THE FIRST COMPETITIVE ANTOGONIST OF THE SENSORY NEURON EXCITANTS CAPSAICIN AND RESINIFERATOXIN", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, (19940624), vol. 37, no. 13, ISSN 0022-2623, pages 1942 - 1954, XP000576031 [A] 15-17,19 * the whole document * DOI: http://dx.doi.org/10.1021/jm00039a006
		[A] - DRAY A, "NEUROPHARMACOLOGICAL MECHANISMS OF CAPSAICIN AND RELATED SUBSTANCES", BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, (19920818), vol. 44, no. 4, ISSN 0006-2952, pages 611 - 615, XP000576776 [A] 15-17,19 * the whole document * DOI: http://dx.doi.org/10.1016/0006-2952(92)90393-W
		[A] - LEE J ET AL, "3-Acyloxy-2-phenalkylpropyl Amides and Esters of Homovanillic Acid as Novel Vanilloid Receptor Agonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, (19991018), vol. 9, no. 20, ISSN 0960-894X, pages 2909 - 2914, XP004180508 [A] 15-17,19 * the whole document * DOI: http://dx.doi.org/10.1016/S0960-894X(99)00513-2
		[A] - PERKINS M N ET AL, "CAPSAZEPINE REVERSAL OF THE ANTINOCICEPTIVE ACTION OF CASAICIN IN VIVO", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, (19921001), vol. 107, no. 2, ISSN 0007-1188, pages 329 - 333, XP000576708 [A] 15-17,19 * the whole document *
		[A] - SZALLASI A ET AL, "A NOVEL AGONIST, PHORBOL 12-PHENYLACETATE 13-ACETATE 20-HOMOVANILLATE, ABOLISHES POSITIVE COOPERATIVITY OF BINDING BY THE VANILLOID RECEPTOR", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, (1996), vol. 299, no. 1 - 3, ISSN 0014-2999, pages 221 - 228, XP002059195 [A] 15-17,19 * the whole document * DOI: http://dx.doi.org/10.1016/0014-2999(95)00864-0
		[A] - SZALLASI A ET AL, "BINDING OF NEUROLEPTIC DRUG (TRIFLUOPERAZINE AND RIMCAZOLE) TO VANILLOID RECEPTORS IN PORCINE DORSAL HORN", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, (19960318), vol. 298, no. 3, ISSN 0014-2999, pages 321 - 327, XP001028115 [A] 15-17,19 * the whole document * DOI: http://dx.doi.org/10.1016/0014-2999(95)00805-5
		[PX] - LIEDTKE WOLFGANG ET AL, "Vanilloid receptor-related osmotically activated channel (VR-OAC), a candidate vertebrate osmoreceptor.", CELL, (20001027), vol. 103, no. 3, ISSN 0092-8674, pages 525 - 535, XP002178632 [PX] 1-20 * the whole document * DOI: http://dx.doi.org/10.1016/S0092-8674(00)00143-4
		[PX] - WAHL P ET AL, "IODO-RESINIFERATOXIN, A NEW POTENT VANILLOID RECEPTOR ANTAGONIST", MOLECULAR PHARMACOLOGY, BALTIMORE, MD, US, (200101), vol. 59, no. 1, ISSN 0026-895X, pages 9 - 15, XP001028112 [PX] 15-17,19 * the whole document *
		[PX] - SZALLASI ARPAD ET AL, "New perspectives on enigmatic vanilloid receptors.", TRENDS IN NEUROSCIENCES, (200010), vol. 23, no. 10, ISSN 0166-2236, pages 491 - 497, XP001027974 [PX] 1,15-17,19 * the whole document * DOI: http://dx.doi.org/10.1016/S0166-2236(00)01630-1
		[T] - EMBL, (20010906), Database accession no. AAK69487;, XP002178634 [T] 1-12 * abstract *

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p